MEI Pharma Stock Forecast, Price & News

-0.04 (-1.24 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume568,121 shs
Average Volume819,252 shs
Market Capitalization$358.04 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEI Pharma logo

About MEI Pharma

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.55 out of 5 stars

Medical Sector

517th out of 2,097 stocks

Pharmaceutical Preparations Industry

251st out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than MEI Pharma?

Wall Street analysts have given MEI Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MEI Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, September 8th 2021.
View our earnings forecast for MEI Pharma

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.12. The business had revenue of $2.42 million for the quarter, compared to analyst estimates of $4.55 million. MEI Pharma had a negative net margin of 154.77% and a negative trailing twelve-month return on equity of 61.56%.
View MEI Pharma's earnings history

How has MEI Pharma's stock price been impacted by Coronavirus?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MEIP stock has increased by 105.2% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MEIP?

6 brokers have issued twelve-month target prices for MEI Pharma's stock. Their forecasts range from $5.50 to $12.00. On average, they expect MEI Pharma's stock price to reach $9.10 in the next year. This suggests a possible upside of 186.2% from the stock's current price.
View analysts' price targets for MEI Pharma
or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Dr. Daniel P. Gold, Pres, CEO & Director (Age 67, Pay $1.14M)
  • Mr. Brian G. Drazba B.A., CPA, CPA, CFO & Sec. (Age 60, Pay $603k)
  • Mr. David M. Urso B.A., Esq., J.D., COO & Gen. Counsel (Age 57, Pay $718.75k)
  • Dr. Robert D. Mass, Strategic Advisor (Age 67, Pay $294.59k)
  • Mr. David A. Walsey J.D., L.L.M., VP of IR & Corp. Communications
  • Mr. Brian T. Powl, Sr. VP of Marketing
  • Ms. Jamie A. Tereschuck, VP of HR
  • Dr. Ofir Moreno, Sr. VP of Pharmaceutical Sciences
  • Dr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 58)
  • Dr. Richard G. Ghalie, Chief Medical Officer (Age 63)

Who are some of MEI Pharma's key competitors?

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.63%), Wasatch Advisors Inc. (5.92%), First Light Asset Management LLC (5.67%), BVF Inc. IL (3.19%), Sectoral Asset Management Inc (1.74%) and Renaissance Technologies LLC (1.59%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BVF Inc. IL, Panagora Asset Management Inc., Millennium Management LLC, Point72 Asset Management L.P., Morgan Stanley, Northern Trust Corp, and DAFNA Capital Management LLC.
View insider buying and selling activity for MEI Pharma
or view top insider-selling stocks.

Which major investors are buying MEI Pharma stock?

MEIP stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Sectoral Asset Management Inc, Wasatch Advisors Inc., Altium Capital Management LP, Woodline Partners LP, BlackRock Inc., Goldman Sachs Group Inc., and Acadian Asset Management LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma
or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.18.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $358.04 million and generates $28.91 million in revenue each year. The company earns $-46,010,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.